Dr. Levy has served on Madrigal’s Board of Directors since August of 2016. Dr. Levy also serves on the board of directors of ProTara Therapeutics, Inc., Kodiak Sciences Inc. and Kiniksa Pharmaceuticals, Ltd., each a publicly-held pharmaceutical company. Dr. Levy previously served on the board of Aquinox Pharmaceuticals, Inc. Previously, from December 2016 to May 2019, Dr. Levy was a part-time Senior Advisor for Baker Bros. Advisors, L.P., a firm that primarily manages long-term investment funds focused on publicly traded life sciences companies. Dr. Levy served as Executive Vice President and Chief Drug Development Officer at Incyte from January 2009 until his retirement in April 2016, and as Senior Vice President of Drug Development at Incyte from August 2003 to January 2009. Prior to joining Incyte, Dr. Levy served as Vice President, Biologic Therapies, at Celgene Corporation, a publicly-held biopharmaceutical company, from 2002 to 2003. From 1997 to 2002, Dr. Levy served in various executive positions with DuPont Pharmaceuticals Company, first as Vice President, Regulatory Affairs and Pharmacovigilence, and thereafter as Vice President, Medical and Commercial Strategy. Dr. Levy served at Novartis, and its predecessor company Sandoz, from 1991 to 1997 in positions of increasing responsibility in clinical research and regulatory affairs. Dr. Levy has more than 30 years’ experience in the pharmaceutical and biotechnology industries through his prior positions at Incyte, Celgene, DuPont Pharmaceuticals and Novartis, has extensive clinical research, regulatory and product development skills and has worked in multiple therapeutic areas. Prior to joining the pharmaceutical industry, Dr. Levy served as an Assistant Professor of Medicine at the UCLA School of Medicine. Dr. Levy is Board Certified in Internal Medicine and Gastroenterology and received his A.B. in Biology from Brown University, his M.D. from the University of Pennsylvania School of Medicine, and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA.
What is Richard S. Levy's net worth?
The estimated net worth of Richard S. Levy is at least $1.99 million as of April 1st, 2024. Dr. Levy owns 10,298 shares of Madrigal Pharmaceuticals stock worth more than $1,990,912 as of April 26th. This net worth approximation does not reflect any other assets that Dr. Levy may own. Learn More about Richard S. Levy's net worth.
How do I contact Richard S. Levy?
Has Richard S. Levy been buying or selling shares of Madrigal Pharmaceuticals?
During the past quarter, Richard S. Levy has sold $2,832,280.00 of Madrigal Pharmaceuticals stock. Most recently, Richard S. Levy sold 11,000 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $257.48, for a transaction totalling $2,832,280.00. Following the completion of the sale, the director now directly owns 10,298 shares of the company's stock, valued at $2,651,529.04. Learn More on Richard S. Levy's trading history.
Who are Madrigal Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Madrigal Pharmaceuticals?
During the last twelve months, Madrigal Pharmaceuticals insiders bought shares 4 times. They purchased a total of 226,067 shares worth more than $43,382,043.47. During the last twelve months, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 154,796 shares worth more than $33,116,646.13. The most recent insider tranaction occured on April, 8th when CMO Rebecca Taub sold 2,676 shares worth more than $658,269.24. Insiders at Madrigal Pharmaceuticals own 23.9% of the company.
Learn More about insider trades at Madrigal Pharmaceuticals. Information on this page was last updated on 4/8/2024.
